This label expansion adds a new revenue driver for HUTCHMED's partnered asset; watch for NRDL inclusion for this indication to accelerate volume. The existing commercial infrastructure via AstraZeneca and prior NRDL listing for lung cancer de-risks launch execution. Monitor upcoming quarterly results for initial prescription trends.
Price Chart
Executive Summary
HUTCHMED (HCM) announces conditional NMPA approval in China for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior systemic treatments. This is the third approved indication for ORPATHYS in China, supported by a pivotal Phase II study showing a 32.3% objective response rate, and the drug is already on the National Reimbursement Drug List for its prior lung cancer indication, providing a clear commercial path alongside partner AstraZeneca.
Key Facts
- ORPATHYS (savolitinib) received conditional NMPA approval for MET-amplified advanced GC/GEJ adenocarcinoma after >=2 prior systemic treatments
- Approval supported by Phase II study (NCT04923932): IRC-assessed ORR 32.3% (95%CI: 21.2%-45.1%), DCR 63.1%, median DoR 9.7 months, median PFS 4.0 months
- Estimated annual incidence of MET-amplified gastric cancer in China is ~18,000 patients (~4-6% of all gastric cancer cases)
- This is the third approved indication for ORPATHYS in China; it is already on the NRDL (since March 2023) for prior lung cancer indication
- Drug is jointly developed with AstraZeneca, which commercializes it in China
Financial Impact
Expands the addressable patient population for ORPATHYS by adding ~18,000 incident MET-amplified GC/GEJ patients per year in China. Revenue contribution will depend on NRDL pricing, market penetration, and duration of therapy (median DoR 9.7 months). As the first selective MET inhibitor approved for this indication, near-term revenue upside is clear but not yet quantifiable from the filing alone.
Risk Factors
- Conditional approval may require confirmatory trial data; failure to meet post-marketing requirements could lead to label restriction
- MET amplification prevalence is only ~4-6% of gastric cancer, limiting absolute patient numbers
- Pricing and NRDL negotiation for this specific indication are unknown; reimbursement terms could constrain margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000047 |
| Document: hcm-20260702x6k.htm | 0001648257-26-000047 |
| Document: 0001648257-26-000047-index-headers.html | 0001648257-26-000047 |
| Document: 0001648257-26-000047-index.html | 0001648257-26-000047 |
| Document: 0001648257-26-000047.txt | 0001648257-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access